

---

## ExpreS<sup>2</sup>ion will attend and present its ExpreS<sup>2</sup> technology platform at several key events in March and April

ExpreS<sup>2</sup>ion Biotech Holding AB's affiliate ExpreS<sup>2</sup>ion Biotechnologies ApS ("ExpreS<sup>2</sup>ion") will participate at several key events in March and April, including ISBiotech, March 4-6, in Norfolk, VA, USA, Sedermeradagen, March 12, in Copenhagen, Denmark, and World Vaccine Congress, April 15-17, in Washington, DC, USA.

During these and additional scientific and business partnering meetings, ExpreS<sup>2</sup>ion will present the advantages of the ExpreS<sup>2</sup> platform for vaccine discovery, development and GMP production. Recent publications have documented progress in projects using the platform, including the RH5.1 blood-stage malaria vaccine development obtaining positive clinical Phase I/IIa trial results ([link to October 31, 2018 press release](#)) and the VAR2CSA placenta-borne malaria vaccine development obtaining positive clinical Phase I trial results ([link to January 10, 2019 press release](#)).

*"These events provide excellent opportunities for us to present the company and our ExpreS<sup>2</sup> platform projects to customers or potential partners. We invite everyone with an interest in our Company, our platform, or our projects to contact me and my fellow colleagues, so we can meet and discuss any questions, requests or upcoming opportunities within vaccine development and diagnostics,"* says ExpreS<sup>2</sup>ion's CEO Dr. Steen Klysner.

ExpreS<sup>2</sup>ion will participate in the following activities in March and April, 2019:

### **ISBiotech 9<sup>th</sup> Spring Meeting, March 4-6, Norfolk, VA, USA**

Attend the company presentation by our CSO, Dr. Wian de Jongh, on Development of *Drosophila* S2-Based Vaccine Production Processes. More information at [ISBiotech's website](#).

### **Sedermeradagen, March 12, Copenhagen, Denmark**

See the company presentation by our CEO, Dr. Steen Klysner, at this investor event either online or attend the meeting by reserving a seat at [Sedermeradagen's website](#)

### **BIO-Europe Spring, March 25-27, Vienna, Austria**

To pre-arrange business meetings with ExpreS<sup>2</sup>ion representatives, please contact us via email on [info@expreS2ionbio.com](mailto:info@expreS2ionbio.com). More information at [BIO-Europe's website](#).

### **BioProcess International Europe (BPI), April 2-5, Vienna, Austria**

To pre-arrange technical and business meetings with ExpreS<sup>2</sup>ion representatives, please contact us via email on [info@expreS2ionbio.com](mailto:info@expreS2ionbio.com). More information at [BPI Europe's website](#).

### **13<sup>th</sup> World Immune Regulation Meeting (WIRM), April 6-9, Davos, Switzerland**

To pre-arrange technical and business meetings with ExpreS<sup>2</sup>ion representatives, please contact us via email on [info@expreS2ionbio.com](mailto:info@expreS2ionbio.com). More information at [WIRM's website](#).

### **World Vaccine Congress (WVC), April 14-17, Washington, DC, USA**

To learn more about ExpreS<sup>2</sup> and our proven, effective solutions for recombinant protein development and production, please contact us via email on [info@expreS2ionbio.com](mailto:info@expreS2ionbio.com). More information at [WVC's website](#).

### **Certified Adviser**

Sedermera Fondkommission  
E-mail: [CA@sedermera.se](mailto:CA@sedermera.se)  
Telephone: +46 40-615 14 10

**For further information about ExpreS<sup>2</sup>ion, please contact:**

Dr. Steen Klysner, CEO

Telephone: +45 2062 9908

E-mail: [sk@expres2ionbio.com](mailto:sk@expres2ionbio.com)

---

**About ExpreS<sup>2</sup>ion**

ExpreS<sup>2</sup>ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS<sup>2</sup>ion Biotech Holding AB with company register number 559033-3729. The subsidiary has developed a unique proprietary platform technology, ExpreS<sup>2</sup>, that can be used for fast and efficient preclinical and clinical development as well as robust production of complex proteins for new vaccines and diagnostics. Since the Company was founded in 2010, it has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies, demonstrating superior efficiency and success rates. In addition, ExpreS<sup>2</sup>ion develops novel VLP based vaccines through the joint venture AdaptVac ApS which was founded in 2017.